Novo hemophila drug approved

Share this article:

The FDA approved Novo Nordisk's Hemophilia A drug Novoeight. The Danish drug maker said in a statement Wednesday that it expects to have the drug on the US market during 2015's second quarter.

The treatment is for a type of hemophilia that typically affects men, and is the result of a missing or malfunctioning factor VIII protein.

The drug was among an elite list of medications approved during the government's 16-day shutdown.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.